New injection aims to make heart plaque less dangerous
NCT ID NCT06788431
First seen Jan 07, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This early-phase trial tests an injectable drug called IMC-001 in 18 people who recently had a heart attack or unstable angina. The goal is to see if it can safely stabilize fatty plaque in the heart arteries, making it less likely to rupture. Participants receive either the drug or a placebo, plus standard heart medications, and are followed for 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital,Shanghai
RECRUITINGShanghai, Shanghai Municipality, China
-
The First Affiliated Hospital of Nanyang Medical College
RECRUITINGNanyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMC-001
What this could lead to
If it works, this could point toward a new injection to help stabilize dangerous plaque in heart arteries, potentially reducing the risk of future heart attacks.
What could go wrong
This is a very early, small trial with only 18 people. It primarily tests safety, not effectiveness. The drug may not improve plaque stability or could have side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.